Biora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:31 pm EST
Share
Biora Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 73.45 million compared to USD 5.11 million a year ago. Basic loss per share from continuing operations was USD 4.89 compared to USD 1.99 a year ago. Diluted loss per share from continuing operations was USD 4.89 compared to USD 1.99 a year ago. Basic loss per share was USD 4.89 compared to USD 0.68 a year ago. Diluted loss per share was USD 4.89 compared to USD 0.68 a year ago.
For the nine months, sales was USD 0.004 million compared to USD 0.291 million a year ago. Net loss was USD 108.7 million compared to USD 24.44 million a year ago. Basic loss per share from continuing operations was USD 8.54 compared to USD 4.78 a year ago. Diluted loss per share from continuing operations was USD 8.54 compared to USD 4.78 a year ago. Basic loss per share was USD 8.54 compared to USD 3.3 a year ago. Diluted loss per share was USD 8.54 compared to USD 3.3 a year ago.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Companyâs pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
BIORA THERAPEUTICS, INC. 
